Souhaitez-vous accéder aux communiqués récents ?

The results of the Phase 2 SPRING trial assessing nebokitug in patients with primary sclerosing cholangitis were published in Gastroenterology,

CEO Dr. Adi Mor will present a corporate overview and meet with investors at Oppenheimer's Movers in Rare Disease Summit on Dec. 11, 2025 in NYC.

In the 3rd quarter Chemomab advanced preparations for initiating the Phase 3 trial of nebokitug in PSC, with FDA and EMA aligning on overall study design.

Chemomab announced three presentations "of distinction" at AASLD The Liver Meeting® 2025 featuring clinical data from the nebokitug Phase 2 trial in PSC.

Chemomab will participate in the H.C. Wainwright 27th Annual Global Investment Conference Sept. 5-9, 2025, with a webcast presentation and 1x1 meetings.

Phase 3 preparations are ongoing while Chemomab is advancing partnering options for executing the nebokitug Phase 3 program. Runway through end of Q2 2026.

Positive nebokitug PSC Phase 2 data was presented in an oral session at BSG Live’25, the scientific meeting of the British Society for Gastroenterology.

FDA agreement on CMC requirements and the timing of non-clinical toxicology testing are milestones further advancing nebokitug towards a PSC Phase 3 trial.

New patents in China and Russia further strengthen nebokitug's extensive intellectual property portfolio in the US, Europe and other major territories.

These major milestones in Q1 support advancement of Nebokitug to Phase 3 and position It to potentially become the first FDA-approved treatment for PSC.